Drugging the human methylome: An emerging modality for reversible control of aberrant gene transcription

Current Opinion in Chemical Biology

Volumn 17, Issue 3, 2013, Pages 369-378

  Wigle, Tim J ^a   Copeland, Robert A ^a  

^a EPIZYME INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYCLOHEXYL N (1 ISOPROPYL 4 PIPERIDINYL) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY] 4 QUINAZOLINAMINE; ARGININE; AZ 505; BIPYRIDINE DERIVATIVE; CYCLOPROPYLAMINE DERIVATIVE; ENZYME INHIBITOR; EPZ 004777; EPZ 005687; EPZ 5676; GSK 126; GSK J1; HISTONE H3; HISTONE H4; LYSINE; LYSINE DEMETHYLASE; METHYLTRANSFERASE; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1,4 DIAZEPIN 1 YL) 6,7 DIMETHOXY 4 QUINAZOLINAMINE; N OXALYLAMINO ACID DERIVATIVE; S ADENOSYLMETHIONINE; UNC 1215; UNC 669; UNCLASSIFIED DRUG; WDR 50103;

DNA METHYLATION; DRUG ACTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; GENE MUTATION; GENETIC TRANSCRIPTION; GENOME; HISTONE MODIFICATION; HUMAN; IC 50; LIGAND BINDING; NONHUMAN; PHARMACOPHORE; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN DOMAIN; PROTEIN METHYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SEQUENCE ANALYSIS; TRANSCRIPTION REGULATION;

AMINO ACID SEQUENCE; ANIMALS; DRUG DISCOVERY; HUMANS; METHYLATION; MOLECULAR SEQUENCE DATA; NEOPLASMS; PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84878872227     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2013.03.035     Document Type: Review

References (64)

1. Copeland R.A., Solomon M.E., Richon V.M. Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov 2009, 8:724-732.
2. Lee Y.H., Stallcup M.R. Minireview: protein arginine methylation of nonhistone proteins in transcriptional regulation. Mol Endocrinol 2009, 23:425-433.
3. Zhang X., Wen H., Shi X. Lysine methylation: beyond histones. Acta Biochim Biophys Sin (Shanghai) 2012, 44:14-27.
4. Richon V.M., Johnston D., Sneeringer C.J., Jin L., Majer C.R., Elliston K., Jerva L.F., Scott M.P., Copeland R.A. Chemogenetic analysis of human protein methyltransferases. Chem Biol Drug Des 2011, 78:199-210.
5. Arrowsmith C.H., Bountra C., Fish P.V., Lee K., Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012, 11:384-400.
6. Forneris F., Binda C., Vanoni M.A., Mattevi A., Battaglioli E. Histone demethylation catalysed by LSD1 is a flavin-dependent oxidative process. FEBS Lett 2005, 579:2203-2207.
7. Tsukada Y., Fang J., Erdjument-Bromage H., Warren M.E., Borchers C.H., Tempst P., Zhang Y. Histone demethylation by a family of JmjC domain-containing proteins. Nature 2006, 439:811-816.
8. Cuthbert G.L., Daujat S., Snowden A.W., Erdjument-Bromage H., Hagiwara T., Yamada M., Schneider R., Gregory P.D., Tempst P., Bannister A.J., et al. Histone deimination antagonizes arginine methylation. Cell 2004, 118:545-553.
9. Wang Y., Wysocka J., Sayegh J., Lee Y.H., Perlin J.R., Leonelli L., Sonbuchner L.S., McDonald C.H., Cook R.G., Dou Y., et al. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 2004, 306:279-283.
10. Maurer-Stroh S., Dickens N.J., Hughes-Davies L., Kouzarides T., Eisenhaber F., Ponting C.P. The Tudor domain 'Royal Family': Tudor, plant Agenet, Chromo, PWWP and MBT domains. Trends Biochem Sci 2003, 28:69-74.
11. Adams-Cioaba M.A., Min J. Structure and function of histone methylation binding proteins. Biochem Cell Biol 2009, 87:93-105.
12. Sanchez R., Zhou M.M. The PHD finger: a versatile epigenome reader. Trends Biochem Sci 2011, 36:364-372.
13. Liu K., Guo Y., Liu H., Bian C., Lam R., Liu Y., Mackenzie F., Rojas L.A., Reinberg D., Bedford M.T., et al. Crystal structure of TDRD3 and methyl-arginine binding characterization of TDRD3, SMN and SPF30. PLoS One 2012, 7:e30375.
14. Copeland R.A., Moyer M.P., Richon V.M. Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics. Oncogene 2013, 32:939-946.
15. Morin R.D., Johnson N.A., Severson T.M., Mungall A.J., An J., Goya R., Paul J.E., Boyle M., Woolcock B.W., Kuchenbauer F., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010, 42:181-185.
16. Morin R.D., Mendez-Lago M., Mungall A.J., Goya R., Mungall K.L., Corbett R.D., Johnson N.A., Severson T.M., Chiu R., Field M., et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476:298-303.
17. Lohr J.G., Stojanov P., Lawrence M.S., Auclair D., Chapuy B., Sougnez C., Cruz-Gordillo P., Knoechel B., Asmann Y.W., Slager S.L., et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012, 109:3879-3884.
18. Sneeringer C.J., Scott M.P., Kuntz K.W., Knutson S.K., Pollock R.M., Richon V.M., Copeland R.A. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A 2010, 107:20980-20985.
19. Wigle T.J., Knutson S.K., Jin L., Kuntz K.W., Pollock R.M., Richon V.M., Copeland R.A., Scott M.P. The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS Lett 2011, 585:3011-3014.
20. Majer C.R., Jin L., Scott M.P., Knutson S.K., Kuntz K.W., Keilhack H., Smith J.J., Moyer M.P., Richon V.M., Copeland R.A., et al. A687V EZH2 is a gain-of-function mutation found in lymphoma patients. FEBS Lett 2012, 586:3448-3451.
21. McCabe M.T., Graves A.P., Ganji G., Diaz E., Halsey W.S., Jiang Y., Smitheman K.N., Ott H.M., Pappalardi M.B., Allen K.E., et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci U S A 2012, 109:2989-2994.
22. Barry E.R., Corry G.N., Rasmussen T.P. Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development. Expert Opin Ther Targets 2010, 14:405-418.
23. Bernt K.M., Armstrong S.A. Targeting epigenetic programs in MLL-rearranged leukemias. Hematology Am Soc Hematol Educ Program 2011, 2011:354-360.
24. Vedadi M., Barsyte-Lovejoy D., Liu F., Rival-Gervier S., Allali-Hassani A., Labrie V., Wigle T.J., Dimaggio P.A., Wasney G.A., Siarheyeva A., et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol 2011, 7:566-574.
25. Daigle S.R., Olhava E.J., Therkelsen C.A., Majer C.R., Sneeringer C.J., Song J., Johnston L.D., Scott M.P., Smith J.J., Xiao Y., et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011, 20:53-65.
26. Basavapathruni A., Jin L., Daigle S.R., Majer C.R., Therkelsen C.A., Wigle T.J., Kuntz K.W., Chesworth R., Pollock R.M., Scott M.P., et al. Conformational adaptation drives potent. selective and durable inhibition of the human protein methyltransferase DOT1L. Chem Biol Drug Des 2012, 80:971-980.
27. Knutson S.K., Wigle T.J., Warholic N.M., Sneeringer C.J., Allain C.J., Klaus C.R., Sacks J.D., Raimondi A., Majer C.R., Song J., et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012, 8:890-896.
28. McCabe M.T., Ott H.M., Ganji G., Korenchuk S., Thompson C., Van Aller G.S., Liu Y., Graves A.P., Iii A.D., Diaz E., et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492:108-112.
29. Guibourt N: Phenylcyclopropylamine derivatives and their medical use. International Patent July 2010, WO2010/084160.
30. Kruidenier L., Chung C.W., Cheng Z., Liddle J., Che K., Joberty G., Bantscheff M., Bountra C., Bridges A., Diallo H., et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 2012, 488:404-408.
31. Harris W.J., Huang X., Lynch J.T., Spencer G.J., Hitchin J.R., Li Y., Ciceri F., Blaser J.G., Greystoke B.F., Jordan A.M., et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012, 21:473-487.
32. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
33. Wang G.G., Song J., Wang Z., Dormann H.L., Casadio F., Li H., Luo J.L., Patel D.J., Allis C.D. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature 2009, 459:847-851.
34. Reader J.C., Meekins J.S., Gojo I., Ning Y. A novel NUP98-PHF23 fusion resulting from a cryptic translocation t(11;17)(p15;p13) in acute myeloid leukemia. Leukemia 2007, 21:842-844.
35. Panagopoulos I., Micci F., Thorsen J., Gorunova L., Eibak A.M., Bjerkehagen B., Davidson B., Heim S. Novel fusion of MYST/Esa1-associated factor 6 and PHF1 in endometrial stromal sarcoma. PLoS One 2012, 7:e39354.
36. Herold J.M., Wigle T.J., Norris J.L., Lam R., Korboukh V.K., Gao C., Ingerman L.A., Kireev D.B., Senisterra G., Vedadi M., et al. Small-molecule ligands of methyl-lysine binding proteins. J Med Chem 2011, 54:2504-2511.
37. Senisterra G., Wu H., Allali-Hassani A., Wasney G.A., Barsyte-Lovejoy D., Dombrovski L., Dong A., Nguyen K.T., Smil D., Bolshan Y., et al. Small molecule inhibition of MLL activity by disruption of its interaction with WDR5. Biochem J 2013, 449:151-159.
38. James L.I., Barsyte-Lovejoy D., Zhong N., Krichevsky L., Korboukh V.K., Herold J.M., MacNevin C.J., Norris J.L., Sagum C.A., Tempel W., et al. Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nat Chem Biol 2013, 9:184-191.
39. Varambally S., Cao Q., Mani R.S., Shankar S., Wang X., Ateeq B., Laxman B., Cao X., Jing X., Ramnarayanan K., et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008, 322:1695-1699.
40. Wang G.G., Cai L., Pasillas M.P., Kamps M.P. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol 2007, 9:804-812.
41. Chesi M., Nardini E., Lim R.S., Smith K.D., Kuehl W.M., Bergsagel P.L. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene. MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998, 92:3025-3034.
42. Keats J.J., Reiman T., Maxwell C.A., Taylor B.J., Larratt L.M., Mant M.J., Belch A.R., Pilarski L.M. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003, 101:1520-1529.
43. Rosati R., La Starza R., Veronese A., Aventin A., Schwienbacher C., Vallespi T., Negrini M., Martelli M.F., Mecucci C. NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood 2002, 99:3857-3860.
44. Angrand P.O., Apiou F., Stewart A.F., Dutrillaux B., Losson R., Chambon P. NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines. Genomics 2001, 74:79-88.
45. Hammerman P.S., Hayes D.N., Wilkerson M.D., Schultz N., Bose R., Chu A., Collisson E.A., Cope L., Creighton C.J., Getz G., et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525.
46. Ceol C.J., Houvras Y., Jane-Valbuena J., Bilodeau S., Orlando D.A., Battisti V., Fritsch L., Lin W.M., Hollmann T.J., Ferre F., et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 2011, 471:513-517.
47. Komatsu S., Imoto I., Tsuda H., Kozaki K.I., Muramatsu T., Shimada Y., Aiko S., Yoshizumi Y., Ichikawa D., Otsuji E., et al. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis 2009, 30:1139-1146.
48. Yang Z.Q., Imoto I., Fukuda Y., Pimkhaokham A., Shimada Y., Imamura M., Sugano S., Nakamura Y., Inazawa J. Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer Res 2000, 60:4735-4739.
49. Northcott P.A., Nakahara Y., Wu X., Feuk L., Ellison D.W., Croul S., Mack S., Kongkham P.N., Peacock J., Dubuc A., et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 2009, 41:465-472.
50. Liu G., Bollig-Fischer A., Kreike B., van de Vijver M.J., Abrams J., Ethier S.P., Yang Z.Q. Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene 2009, 28:4491-4500.
51. Heidenblad M., Lindgren D., Jonson T., Liedberg F., Veerla S., Chebil G., Gudjonsson S., Borg A., Mansson W., Hoglund M. Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors. BMC Med Genomics 2008, 1:3.
52. van Haaften G., Dalgliesh G.L., Davies H., Chen L., Bignell G., Greenman C., Edkins S., Hardy C., O'Meara S., Teague J., et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009, 41:521-523.
53. van Zutven L.J., Onen E., Velthuizen S.C., van Drunen E., von Bergh A.R., van den Heuvel-Eibrink M.M., Veronese A., Mecucci C., Negrini M., de Greef G.E., et al. Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene. Genes Chromosomes Cancer 2006, 45:437-446.
54. Ferguson A.D., Larsen N.A., Howard T., Pollard H., Green I., Grande C., Cheung T., Garcia-Arenas R., Cowen S., Wu J., et al. Structural basis of substrate methylation and inhibition of SMYD2. Structure 2011, 19:1262-1273.
55. Kubicek S., O'Sullivan R.J., August E.M., Hickey E.R., Zhang Q., Teodoro M.L., Rea S., Mechtler K., Kowalski J.A., Homon C.A., et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 2007, 25:473-481.
56. Siarheyeva A., Senisterra G., Allali-Hassani A., Dong A., Dobrovetsky E., Wasney G.A., Chau I., Marcellus R., Hajian T., Liu F., et al. An allosteric inhibitor of protein arginine methyltransferase 3. Structure 2012, 20:1425-1435.
57. Allan M., Manku S., Therrien E., Nguyen N., Styhler S., Robert M.F., Goulet A.C., Petschner A.J., Rahil G., Robert Macleod A., et al. N-Benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1). Bioorg Med Chem Lett 2009, 19:1218-1223.
58. Huynh T., Chen Z., Pang S., Geng J., Bandiera T., Bindi S., Vianello P., Roletto F., Thieffine S., Galvani A., et al. Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1). Bioorg Med Chem Lett 2009, 19:2924-2927.
59. Lee M.G., Wynder C., Schmidt D.M., McCafferty D.G., Shiekhattar R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol 2006, 13:563-567.
60. Ueda R., Suzuki T., Mino K., Tsumoto H., Nakagawa H., Hasegawa M., Sasaki R., Mizukami T., Miyata N. Identification of cell-active lysine specific demethylase 1-selective inhibitors. J Am Chem Soc 2009, 131:17536-17537.
61. Mimasu S., Umezawa N., Sato S., Higuchi T., Umehara T., Yokoyama S. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1. Biochemistry 2010, 49:6494-6503.
62. Rose N.R., Ng S.S., Mecinovic J., Lienard B.M., Bello S.H., Sun Z., McDonough M.A., Oppermann U., Schofield C.J. Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases. J Med Chem 2008, 51:7053-7056.
63. Hamada S., Kim T.D., Suzuki T., Itoh Y., Tsumoto H., Nakagawa H., Janknecht R., Miyata N. Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji C-domain-containing histone lysine demethylase inhibitors. Bioorg Med Chem Lett 2009, 19:2852-2855.
64. Chang K.H., King O.N., Tumber A., Woon E.C., Heightman T.D., McDonough M.A., Schofield C.J., Rose N.R. Inhibition of histone demethylases by 4-carboxy-2,2'-bipyridyl compounds. ChemMedChem 2011, 6:759-764.